Peter Petzelbauer
Principal Investigator:
Peter Petzelbauer Personal webpage
Medical University Vienna Webpage
A new treatment concept for lung injury
Weitere ProjektpartnerInnen:
Sylvia Knapp (Medical University Vienna)
Marcus Schultz (University of Amsterdam, Amsterdam)
Abgeschlossen (01.08.2011 – 31.07.2014) 36 Monate
€ 492.800


Acute lung injury (ALI/ARDS) is a major problem at intense care units with mortality rates in the range of 40%. The main functional impediment in this disease resides at the alveolar-capillary barrier, which normally restricts fluid accumulation within the alveolar space thereby facilitating efficient gas exchange. This barrier is dysfunctional in ALI/ARDS, mainly through pathologic activation of RhoGTPases. Current therapies are only symptomatic, targeted therapies are missing. This project aims to develop new tools to improve alveolar-capillary barrier function through targeted interception of pathologic activation of RhoGTPases. Our unique position consists of the experienced team, access to a new and targeted inhibitor of RhoGTPases, and an unmet medical need with no approved drug on the market. Results of this work will serve as a starting point for a pharma-partner to initiate cost-intensive regulatory preclinical drug development.


Diese Seite verwendet Cookies. Durch das Nutzen dieser Seite sind Sie mit der Verwendung von Cookies einverstanden. Details finden Sie hier.